Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 879-888

  Borras Blasco J ^a   Navarro Ruiz, A ^b   Borras C ^c   Castera E ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Adverse drug reactions; HAART; HIV; Skin

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CORTICOSTEROID; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETHINYLESTRADIOL; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG;

ABNORMAL LABORATORY RESULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTHRALGIA; BODY FAT DISTRIBUTION; BULLOUS SKIN DISEASE; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAPHORESIS; DIARRHEA; DISEASE SEVERITY; DRESS SYNDROME; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RECHALLENGE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EOSINOPHILIA; ERYTHEMA; ERYTHEMA MULTIFORME; EXANTHEMATOUS PUSTULOSIS; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HAIR LOSS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPOTENSION; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; JOINT STIFFNESS; LACTIC ACIDOSIS; LETHARGY; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LICHENOID ERUPTION; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; LUNG DISEASE; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALAISE; MONOTHERAPY; MOUTH ULCER; MYALGIA; NAIL DISEASE; NAUSEA; OBESITY; PHOTOSENSITIVITY; PNEUMONIA; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; RIGOR; SCLERODERMA; SIDE EFFECT; SKIN DISCOLORATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THROAT DISEASE; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; URTICARIA; VOMITING;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; SKIN DISEASES;

EID: 54849410704     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn292     Document Type: Review

References (122)

1. Crum NF, Riffenburgh RH, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194-200.
2. González-Martín G, Yañez CG, González-Contreras L et al Adverse drug reactions (ADRs) in patients with HIV infection. prospective study. Int J Clin Pharmacol Ther 1999; 37: 34-40.
3. Manzardo C, Zaccarelli M, Agüero F et al. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 2007; 46 Suppl 1: S9-18.
4. Hernández-Salazar A, Rosales SP, Rangel-Frausto S et al. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37: 899-902.
5. Nigen S, Knowles SR, Shear NH. Drug eruptions: Approaching the diagnosis of drug-induced skin diseases. J Drug Dermatol 2003; 2: 278-99.
6. Litt J. Drug Eruption Reference Manual. New York, NY: Parthenon, 2000.
7. Revuz J, Valeyrie-Allanore L. Drug reactions. In: Bolognia JL, Jorrizo JL, Rapini RP, eds. Dermatology. London: Mosby, 2003; 333-53.
8. Breathnach SM, Hinter H. Adverse Drug Reactions and the Skin. Oxford: Blackwell Scientific Publications, 1992.
9. Carr A, Samaras K, Chisolm DJ et al. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 352: 1881-3.
10. Piraccini BM, Iorizzo M, Antonucci A et al. Drug-induced nail abnormalities. Expert Opin Drug Saf 2004; 3: 57-65.
11. Tan EK, Grattan CE. Drug-induced urticaria. Expert Opin Drug Saf 2004; 3: 471-84.
12. Muller BA. Urticaria and angioedema: A practical approach. Am Fam Physician 2004; 69: 1123-8.
13. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother 1997; 31 633-5.
14. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
15. Moshfeghi M, Mandler HD. Ciprofloxacin-induced toxic epidermal necrolysis. Ann Pharmacother 1993; 27: 1467-9.
16. Revuz JE, Roujeau JC. Advances in toxic epidermal necrolysis. Semin Cutan Med Surg 1996; 15: 258-66.
17. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
18. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Engl J Med 1995; 333: 1600-7.
19. Borrás-Blasco J, Navarro-Ruiz A, Matarredona J et al. Photo-induced Stevens-Johnson syndrome due to sulfasalazine therapy. Ann Pharmacother 2003; 37: 1241-3.
20. Chia FL, Leong KP. Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol 2007; 7: 304-9.
21. Parrillo SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Allergy Asthma Rep 2007; 7: 243-7.
22. Letko E, Papaliodis DN, Papaliodis GN et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419-36.
23. Garcia-Doval I, LeCleach L, Bocquet H et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-7.
24. Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf 2007; 30: 1011-30.
25. Viard I, Wehrli P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD35 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
26. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6.
27. Stella M, Clemente A, Bollero D et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): Experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007; 33: 452-9.
28. Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
29. Shepherd GM. Hypersensitivity reactions to drugs: Evaluation and management. Mt Sinai J Med 2003; 70: 113-25.
30. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9.
31. Lookingbill DP, Marks JG, Jr. Principles of Dermatology. Philadelphia, PA: WB Saunders, 2000.
32. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: Implications for pharmaceutical care. Pharmacotherapy 2007; 27: 1425-39.
33. Floridia M, Bucciardini R, Fragola V et al. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: Data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/μL). HIV Med 2004; 5: 1-10.
34. Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005; 56: 273-6.
35. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002; 36: 1193-203.
36. Calista D. Maculo-papular rash induced by lopinavir/ritonavir. Eur J Dermatol 2005; 15: 97-8.
37. Ghosn J, Duvivier C, Tubiana R et al. Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir. Clin Infect Dis 2005; 41: 1360-1.
38. Manfredi R, Sabbatani S. Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function. Acquir Immune Defic Syndr 2006; 20: 2399-400.
39. Abbott Laboratories. Kaletra (Lopinavir/Ritonavir) Tablets, (Lopinavir/Ritonavir) Oral Solution Prescribing Information. North Chicago, IL: Abbott Laboratories, 2008.
40. Bongiovanni M, Chiesa E, Monforte A et al. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Dermatol Online J 2003; 9: 28.
41. Borrás-Blasco J, Belda A, Rosique-Robles D et al. Hair loss induced by lopinavir-ritonavir. Pharmacotherapy 2007; 27: 1215-8.
42. Chrysos G, Mikros S, Kokkoris S et al. Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient. J Drugs Dermatol 2007; 6: 742-3.
43. Lenhard JM, Weiel JE, Paulik MA et al. Stimulation of vitamin A(1) acid signalling by the HIV protease inhibitor indinavir. Biochem Pharmacol 2000; 59: 1063-8.
44. Sass JO, Jakob-Sölder B, Heitger A et al. Paronychia with pyogenic granuloma in a child treated with indinavir: The retinoid mediated side effect theory revisited. Dermatology 2000; 200 40-2.
45. Toma E, Devost D, Chow Lan N et al. HIV-protease inhibitors alter retinoic acid synthesis. Acquir Immune Defic Syndr 2001; 15: 1979-84.
46. Pedneault L, Brothers C, Pagano G et al. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clin Ther 2000; 22: 1378-94.
47. Kohli-Pamnani A, Huynh P, Lobo F. Amprenavir-induced maculopapular exanthema followed by desensitization in a patient with late-stage human immunodeficiency virus. Ann Allergy Asthma Immunol 2006; 96: 620-3.
48. Rodriguez-French A, Boghossian J, Gray GE et al. The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1 infected patients. J Acquir immune Defic Syndr 2004; 35: 22-32.
49. Gathe JC, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1-infected patients. Acquir Immune Defic Syndr 2004; 18: 1529-37.
50. Package insert. Lexiva (Fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline. http://us.gsk.com/products/assets/us_lexiva.pdf (2008, date last accessed).
51. Hester EK, Chandler HV, Sims KM. Fosamprenavir: Drug development for adherence. Ann Pharmacother 2006; 40: 1301-10.
52. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2004; 38 1664-74.
53. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
54. Ouagari Z, Tubiana R, Mohand HA et al. Skin rash associated with atazanavir: Report of three cases. Acquir Immune Defic Syndr 2006; 20: 1207-8.
55. Product Information. REYATAZ(R) Oral Capsules, Atazanavir Sulfate Oral Capsules. Princeton, NJ: Bristol-Myers Squibb Company, 2008.
56. Product Information. Aptivus (Tipranavir). Ridgefield, CT: Boehringer Ingelheim, 2007.
57. Gathe J, Cooper DA, Farthing C et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43: 1337-46.
58. Cahn P, Villacian J, Lazzarin A et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43: 1347-56.
59. Tibotec. PREZISTA (Darunavir) Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/H-707-PI-en.pdf (2 July 2008, date last accessed).
60. Madruga JV, Berger D, McMurchie M et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet 2007; 370: 49-58.
61. Derisi M, Ballard C, Abulhosn K et al. Sulfa-associated rash and race are risk factors for non-nucleoside analogue reverse transcriptase inhibitors (NNRTI)-associated rash. Abstract 61. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 30 January 2000-2 February 2000.
62. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
63. Deeks SG. Antiretroviral agents: The next generation. AIDS Clin Care 1998; 10: 33-40.
64. Product Information. SUSTIVA(R) Oral Capsules, Oral Tablets, Efavirenz Oral Capsules, Oral Tablets. Princeton, NJ: Bristol-Myers Squibb Company, 2007.
65. Borrás-Blasco J, Belda A, Rosique-Robles JD et al. Burning mouth syndrome due to efavirenz therapy. Ann Pharmacother 2006; 40: 1471-2.
66. Newell A, Avila C, Rodgers ME. Photosensitivity reaction of efavirenz. Sex Transm Infect 2000; 76: 221.
67. Treudler R, Husak R, Raisova M et al. Efavirenz-induced photoallergic dermatitis in HIV. Acquir Immune Defic Syndr 2001; 15: 1085-6.
68. Yoshimoto E, Konishi M, Takahashi K et al. The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection. Intern Med 2004; 43: 630-1.
69. Domingo P, Barceló M. Efavirenz-induced leukocytoclastic vasculitis. Arch Intern Med 2002; 162: 355-6.
70. Colebunders R, Vanwolleghem T, Meurrens P et al. Efavirenz-associated Stevens-Johnson syndrome. Infection 2004; 32: 306-7.
71. Dona C, Soriano V, Barreiro P et al. Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program. Med Clin (Barc) 2000; 115: 337-8.
72. Behrens GM, Stoll M, Schmidt RE. Pulmonary hypersensitivity reaction induced by efavirenz. Lancet 2001; 357: 1503-4.
73. Bossi P, Colin D, Bricaire F et al. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000; 30: 227-8.
74. Foti JL, Piatt JP. Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child. AIDS Patient Care STDS 2003; 17: 1-3.
75. Moreno-Maroto A, Suárez-Castellano L, Hernández-Cabrera M et al Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J Infect 2006; 52: E39-40.
76. Leung JM, O'Brien JG, Wong HK et al. Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a latino male. Ann Pharmacother 2008; 42: 425-9.
77. Phillips EJ, Kuriakose B, Knowles SR. Efavirenz-induced skin eruption and successful desensitization. Ann Pharmacother 2002; 36: 430-2.
78. Vitezica ZG, Milpied B, Lonjou C et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. Acquir Immune Defic Syndr 2008; 22: 540-1.
79. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
80. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
81. Product Information. INTELENCE(TM) Oral Tablets, Etravirine Oral Tablets. Raritan, NJ: Tibotec Therapeutics, Inc., 2008.
82. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
83. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
84. Maggi P, Ladisa N, Cinori E et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004; 63: 678-81.
85. Shalit P, True A, Thommes JA. QUALITE Investigators. Quality of life and tolerability after administration of enfuvirtide with a thinwalled needle: QUALITE Study. HIV Clin Trials 2007; 8: 24-35.
86. Rice C, Wilantewicz H. Enfuvirtide: Patient acceptance and strategies for managing injection-site reactions. AIDS Read 2006; 16: 470-4.
87. Harris M, Joy R, Larsen G et al. Enfuvirtide (T20) plasma levels using a novel needle-free gas-powered injection system (Biojector) for subcutaneous administration of T20 in treatment-experienced HIV+ patients. In: Abstracts of the Sixth International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, 2005. Abstract 48.
88. Duffalo ML, James CW. Enfuvirtide: Novel agent for the treatment of HIV-1 infection. Ann Pharmacother 2003; 37: 1448-56.
89. Shahar E, Moar C, Pollack S. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction. Acquir Immune Defic Syndr 2005; 19: 451-2.
90. Machado ES, Passoni LF, Sidi LC et al. Successful desensitization of enfuvirtide after a first attempt failure. Acquir Immune Defic Syndr 2006; 20: 2130-1.
91. Quiros-Roldan E, Tirelli V, Torti C et al. Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide. Acquir Immune Defic Syndr 2007; 21: 1388-9.
92. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
93. Product Information. IREAD(R) Oral Tablets, Tenofovir Disoproxil Fumarate Oral Tablets. Foster City, CA: Gilead Sciences, Inc., 2007.
94. Woolley IJ, Veitch AJ, Harangozo CS et al. Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient. Acquir Immune Defic Syndr 2004; 18: 1857-8.
95. Lockhart SM, Rathbun RC, Stephens JR et al. Cutaneous reactions with tenofovir disoproxil fumarate: A report of nine cases. Acquir Immune Defic Syndr 2007; 21: 1370-3.
96. Anderson AM, Bartlett JA. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. Expert Rev Anti Infect Ther 2005; 3: 871-83.
97. Clay PG. The abacavir hypersensitivity reaction: A review. Clin Ther 2002; 24: 1502-14.
98. Dando TM, Scoff LJ. Abacavir plus lamivudine: A review of their combined use in the management of HIV infection. Drugs 2005; 65: 285-302.
99. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59: 591-3.
100. Easterbrook PJ, Waters A, Murad S et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003; 4: 321-4.
101. Shapiro M, Ward KM, Stem JJ. A near-fatal hypersensitivity reaction to abacavir: Case report and literature review. AIDS Read 2001; 11 222-6.
102. Wit FW, Wood R, Horban A et al. Prednisolone does not prevent hypersensitivity reactons in antiretroviral drug regimens containing abacavir with or without nevirapine. Acquir Immune Defic Syndr 2001; 15: 2423-9.
103. Rauch A, Nolan D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43 99-102.
104. Zucman D, Truchis P, Majerholc C et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45: 1-3.
105. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
106. Bossi P, Roujeau JC, Bricaire F et al. Stevens-Johnson syndrome associated with abacavir therapy (letter). Clin Infect Dis 2002; 35: 902.
107. Product Information. ZIAGEN(R) Oral Tablets, Solution, Abacavir Sulfate Oral Tablets, Solution. Research Triangle Park, NC: GlaxoSmithKline, 2006.
108. Montero M, García-Gibert L, Giménez-Arnau AM et al. Toxic epidermal necrolysis associated with abacavir. Enferm Infecc Microbiol Clin 2005; 23: 247.
109. Pollock K, Stebbing J, Bower M et al. Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: A method of assessing toxicity. J Antimicrob Chemother 2006; 58: 227-8.
110. Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: A randomized trial. J Am Med Assoc 2004; 292: 180-9.
111. Benson CA, van der Horst C, LaMarca A et al. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. Acquir Immune Defic Syndr 2004; 18: 2269-76.
112. Product Information. Emtriva(R), Emtricitabine Capsules and Oral Solution. Foster City, CA: Gilead Sciences Inc., 2005.
113. Mondou E, Quinn JB, Shaw A et al. Incidence of skin discoloration across phase 3 clinical trials of emtricitabine (FTC). In: Abstracts of the Fifteenth International AIDS Conference, Bangkok, 2004. Abstract WePeB5916.
114. Nelson M, Schiavone M. Emtricitabine (FTC) for the treatment of HIV infection. Int J Clin Pract 2004; 58: 504-10.
115. Markowitz M, Morales-Ramirez JO, Nguyen BY et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43: 509-15.
116. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
117. Cooper D, Gatell J, Rockstroh J et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 105aLB.
118. Steigbigel R, Kumar P, Eron J et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 105bLB.
119. Product Information. ISENTRESS Oral Tablets, Raltegravir Oral Tablets Whitehouse Station, NJ: Merck & Co, Inc., 2007.
120. Nelson M, Fätkenheuer G, Konourina I et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 104aLB, plus oral presentation.
121. Lalezari J, Mayer H. Efficacy and safety of maraviroc in anti-retroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract H-718a. American Society for Microbiology, Washington, DC, USA.
122. Product Information. SELZENTRY(R) Oral Tablets, Maraviroc Oral Tablets. New York, NY: Pfizer Labs, 2007.